Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial.

Plain-language guide to PMID 31511031 (2019): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 31511031
Journal: Orphanet journal of rare diseases
Year: 2019
Study type: Randomized Controlled Trial
Authors: Yang A et al. (7 authors)
DOI: 10.1186/s13023-019-1195-1
Registered trial: NCT02204163

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Prader-Willi syndrome (PWS) is a rare complex genetic disorder and is characterized by short stature, muscular hypotonia, abnormal body composition, psychomotor retardation, and hyperphagia.

However, systematic studies in infants and toddlers under 2 years of age are lacking.

Who Took Part

PubMed indexes the participants as infants and young children, both men and women.

Height standard deviation score (SDS), body composition, and motor and cognitive development were measured.

How the Study Was Run

The researchers set it up as a randomized, open-label, multicenter and parallel-group study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Body Composition, Cognition, Human Growth Hormone, Prader-Willi Syndrome and Recombinant Proteins.

Author keywords: Growth hormone therapy, Infants and toddlers and Psychomotor development.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Orphanet journal of rare diseases), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.